Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus ifosfamide, etoposide and dexamethasone (SIDE) in relapsed/refractory peripheral T-cell lymphomas
2021-006229-23Phase 2Active
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia-lymphoma (ATLL), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Overall response rate after 4 courses of S-IDE. Started Jan 2022; status: active.
02
Drugs
selinexor
03
Conditions
peripheral T-cell lymphoma (PTCL)adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on 2021-006229-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006229-23.